Barinthus Biotherapeutics Acquired by Beacon Topco | Healthcare M&A Deal

Beacon Topco has acquired Barinthus Biotherapeutics, a healthcare services other business in Maryland, for $27 million. Barinthus Biotherapeutics is a clinical-stage biopharma company developing candidates aimed at metabolic and autoimmune diseases, supporting Beacon Topco’s healthcare M&A strategy. Beacon Topco acquisitions are structured to expand a novel portfolio of therapeutic programs, aligning with strategic acquisition goals in healthcare deals MD and MD acquisitions. The merger acquisition is announced as a strategic acquisition by a Delaware subsidiary of Beacon Topco, with expected implementation via a UK scheme of arrangement and a total consideration reported around $20.25 million to $27 million.